# OnCo record simcere (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/simcere/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "simcere" ;
  schema:name "Simcere Pharmaceutical"@en ;
  schema:alternateName "Jiangsu Simcere Pharmaceutical Co., Ltd."@en, "Simcere Zaiming"@en ;
  schema:description "Simcere is a Nanjing-based pharmaceutical company whose oncology arm, Simcere Zaiming, is running the phase 3 SIMRISE trial of the oral SERD SIM0270 with everolimus in ER-positive breast cancer and markets the anti-PD-1 antibody enlonstobart in China."@en ;
  schema:url <https://onco.cc/companies/simcere/>, <https://www.simcere.com/en/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.simcere.com/en/>, <https://clinicaltrials.gov/search?lead=Simcere> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/cervical/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/sim0270/>, <https://onco.cc/drugs/recombinant-human-endostatin/> ;
  onco:trials <https://onco.cc/trials/simrise/>, <https://onco.cc/trials/nct07361003/>, <https://onco.cc/trials/nct04914598/> .